Anzeige
Mehr »
Login
Freitag, 26.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
181 Leser
Artikel bewerten:
(0)

Sensus Healthcare Announces its Exhibitor Attendance at the 54th Annual ASTRO Meeting

BOCA RATON, Fla., Sept. 28, 2012 /PRNewswire/ --Sensus Healthcare is pleased to announce its exhibitor participation in the 54th Annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Boston, MA on October 28 - 31, 2012. Visit Booth #9054 to learn more about the advanced SRT-100' superficial radiotherapy platform, its unique characteristics and advantages over other NMSC treatment modalities, and how it optimally integrates as a dedicated NMSC treatment solution in the radiation therapy department.

"We cordially invite all ASTRO attendees to take this opportunity to visit our booth in the upcoming 54th Annual ASTRO meeting in Boston, MA and rediscover superficial radiotherapy (SRT) as the optimal radiotherapy solution for treating Non-Melanoma Skin Cancer (NMSC) patients. We are proud to feature our contemporary SRT-100' superficial radiotherapy platform at the meeting and demonstrate to the attendees how they can better their patients' outcomes while contributing to the optimization of their department's workflow, throughput, and operations," stated Joe Sardano, President/CEO, Sensus Healthcare.

About Sensus Healthcare:
Sensus Healthcare specializes in making proven non-melanoma skin cancer solutions more accessible to patients. Our dedicated superficial radiation therapy (SRT) systems are designed specifically to provide an alternative to surgical procedures for basal cell and squamous cell carcinomas. Our mobile, compact SRT-100' systems are used widely by oncologists and dermatologists to bring non-melanoma skin cancer treatment to more patients in more settings. SRT-100' is an ideal treatment modality for non-melanoma skin cancers, thanks to its SharpBeam' characteristics, where only the targeted lesion is being treated, while the surrounding and underlying healthy tissue is spared. The SRT-100' is FDA, CE, and SFDA cleared and is manufactured in the United States of America under the stringent ISO-13485 and GMP quality standards.

Media Contact:
Michelle Verina
Public Relations
561-922-5808 Ext. 100
michelle@sensushealthcare.com

SOURCE Sensus Healthcare

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2012 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.